ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Novavax NanoFlu | influenza
Previous Study | Return to List | Next Study

Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03293498
Recruitment Status : Active, not recruiting
First Posted : September 26, 2017
Last Update Posted : March 29, 2018
Sponsor:
Information provided by (Responsible Party):
Novavax

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Actual Primary Completion Date : March 14, 2018
  Estimated Study Completion Date : September 2018